Tariffs and supply chains bite biotech

Drugmakers are being forced to treat trade policy like a manufacturing ingredient, because a White House proclamation issued on April 2 could put tariffs of up to 100% on some patented medicines and pharmaceutical ingredients coming into the United States. Law firms tracking the order say some rates could start as early as July 2026, which turns a pricing model into a countdown clock. (ropesgray.com) (amundsendavislaw.com) That shock landed while another one was already moving through the system. On April 9, President Donald Trump also announced 50% tariffs on imports from any country supplying weapons to Iran, adding a second layer of uncertainty for companies that move medicine through already stressed global routes. (finance.yahoo.com) (yahoo.com) A modern drug is not made in one place. One company may discover the molecule in Massachusetts, make the active pharmaceutical ingredient in Ireland or India, fill sterile vials in Italy, and ship finished doses through Gulf air hubs or the Strait of Hormuz before they ever reach a United States hospital. (mayerbrown.com) (thinkglobalhealth.org) That route map matters because many medicines are time-sensitive and temperature-sensitive. Marken’s chief strategy officer Dan Bell told Pharmaceutical Executive this week that war-related disruption in the Gulf is hitting exactly the transport lanes biopharma companies use for high-value shipments that cannot sit on a dock or a hot runway. (pharmexec.com) The legal tool behind the drug tariffs is Section 232 of the Trade Expansion Act of 1962. That law lets a president restrict imports on national security grounds, which means the fight is no longer just about customs bills and could become a battle over what counts as a strategic medicine supply. (mayerbrown.com) (taxnews.ey.com) The catch is that “make it in America” is not like moving a sofa factory. A sterile drug plant can take years to permit, build, validate, and inspect, and a biologics line needs specialized tanks, trained staff, and regulator-approved process changes before a single commercial batch can ship. (jdsupra.com) (mayerbrown.com) That is why the immediate response is less “build a new factory tomorrow” and more “rewrite the map.” Medtech companies told Healthcare Dive they are dual-sourcing components, shifting suppliers, reworking contracts, and deciding case by case whether they can absorb tariff costs or pass them on. (medtechdive.com) Drugmakers have fewer easy workarounds than many device companies. If a patented medicine is made in one approved plant with one approved process, changing the source of an ingredient or the site of final fill-finish can trigger fresh regulatory work, new stability data, and new inspections. (jdsupra.com) (ropesgray.com) The result is a strange new calculation for biotech executives. A plant in Europe or Asia may still be cheaper on paper, but a single tariff order, a closed air corridor, or a blocked sea lane can erase that savings faster than a failed clinical trial burns cash. (pharmexec.com) (thinkglobalhealth.org) (ismworld.org) So the biotech story is no longer just about whether a drug works in the body. In April 2026, it is also about whether the vial, ingredient, and shipping lane can survive a tariff regime that is now shaping where the next generation of medicines gets made. (taxnews.ey.com) (pharmexec.com)